All In Biotech

Drug Trial Radar · NCT01015118

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Last checked: Nov 20, 2026Latest source record: Dec 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,366 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,366

Actual

Start

Nov 17, 2009

Primary completion

Apr 1, 2013

Study completion Sep 15, 2016

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Nov 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.

Conditions

  • Ovarian Neoplasms
  • Peritoneal Neoplasms

Interventions

  • PlaceboDrug

    comparator to BIBF 1120

  • PaclitaxelDrug

    Paclitaxel (standard chemo-therapy)

  • BIBF 1120Drug

    comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)

  • CarboplatinDrug

    Carboplatin (standard chemo-therapy)

  • PaclitaxelDrug

    Paclitaxel (standard chemo-therapy)

  • CarboplatinDrug

    Carboplatin (standard chemo-therapy)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria.Time frame: First drug administration to date of disease progression or death whichever occurs first , upto 29 months
  2. PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).Time frame: First drug administration to date of disease progression or death whichever occurs first until final Data Base Lock (DBL) 26September16, upto 62 months

Locations

281 sites in 22 countries. Site status is shown where the registry gives one.

  • 1199.15.10113 Boehringer Ingelheim Investigational Site

    Tucson, Arizona

  • 1199.15.10030 Boehringer Ingelheim Investigational Site

    Long Beach, California

  • 1199.15.10001 Boehringer Ingelheim Investigational Site

    Santa Rosa, California

  • 1199.15.10005 Boehringer Ingelheim Investigational Site

    Englewood, Colorado

  • 1199.15.10028 Boehringer Ingelheim Investigational Site

    New Haven, Connecticut

  • 1199.15.10014 Boehringer Ingelheim Investigational Site

    Orlando, Florida

  • 1199.15.10010 Boehringer Ingelheim Investigational Site

    Augusta, Georgia

  • 1199.15.10004 Boehringer Ingelheim Investigational Site

    Savannah, Georgia

  • 1199.15.10011 Boehringer Ingelheim Investigational Site

    Louisville, Kentucky

  • 1199.15.10003 Boehringer Ingelheim Investigational Site

    Marrero, Louisiana

  • 1199.15.10017 Boehringer Ingelheim Investigational Site

    Detroit, Michigan

  • 1199.15.10103 Boehringer Ingelheim Investigational Site

    Minneapolis, Minnesota

  • 1199.15.10002 Boehringer Ingelheim Investigational Site

    New York, New York

  • 1199.15.10012 Boehringer Ingelheim Investigational Site

    Charlotte, North Carolina

  • 1199.15.10020 Boehringer Ingelheim Investigational Site

    Winston-Salem, North Carolina

  • 1199.15.10019 Boehringer Ingelheim Investigational Site

    Bismarck, North Dakota

  • 1199.15.10024 Boehringer Ingelheim Investigational Site

    Canton, Ohio

  • 1199.15.10025 Boehringer Ingelheim Investigational Site

    Cleveland, Ohio

  • 1199.15.10029 Boehringer Ingelheim Investigational Site

    Cleveland, Ohio

  • 1199.15.10021 Boehringer Ingelheim Investigational Site

    Portland, Oregon

  • 1199.15.10013 Boehringer Ingelheim Investigational Site

    Abington, Pennsylvania

  • 1199.15.10016 Boehringer Ingelheim Investigational Site

    Allentown, Pennsylvania

  • 1199.15.10008 Boehringer Ingelheim Investigational Site

    Providence, Rhode Island

  • 1199.15.10102 Boehringer Ingelheim Investigational Site

    Greenville, South Carolina

  • 1199.15.10006 Boehringer Ingelheim Investigational Site

    Chattanooga, Tennessee

  • 1199.15.10104 Boehringer Ingelheim Investigational Site

    Austin, Texas

  • 1199.15.10100 Boehringer Ingelheim Investigational Site

    Bedford, Texas

  • 1199.15.10107 Boehringer Ingelheim Investigational Site

    Dallas, Texas

  • 1199.15.10108 Boehringer Ingelheim Investigational Site

    Dallas, Texas

  • 1199.15.10110 Boehringer Ingelheim Investigational Site

    Fort Worth, Texas

  • 1199.15.10007 Boehringer Ingelheim Investigational Site

    Houston, Texas

  • 1199.15.10105 Boehringer Ingelheim Investigational Site

    Spokane, Washington

  • 1199.15.10112 Boehringer Ingelheim Investigational Site

    Vancouver, Washington

  • 1199.15.61006 Boehringer Ingelheim Investigational Site

    Camperdown, New South Wales, Australia

  • 1199.15.61001 Boehringer Ingelheim Investigational Site

    Waratah, New South Wales, Australia

  • 1199.15.61004 Boehringer Ingelheim Investigational Site

    Herston, Queensland, Australia

  • 1199.15.61003 Boehringer Ingelheim Investigational Site

    Southe Brisbane, Queensland, Australia

  • 1199.15.61005 Boehringer Ingelheim Investigational Site

    North Terrace, South Australia, Australia

  • 1199.15.61007 Boehringer Ingelheim Investigational Site

    Parkville, Victoria, Australia

  • 1199.15.61002 Boehringer Ingelheim Investigational Site

    Nedlands, Western Australia, Australia

Showing 40 of 281 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.